Tia Turner, a Virginia Commonwealth University M.D.-Ph.D. student, is searching for novel drug combinations to treat triple-negative breast cancer, a disease that currently has no targeted therapies. She conducts her groundbreaking work in the pathology laboratory of VCU Massey Cancer Center researcher Chuck Harrell, Ph.D., member of Massey's Cancer Molecular Genetics research program and an assistant professor of pathology in the VCU School of Medicine.
Over the course of a decade, VCU Massey Cancer Center researcher Devanand Sarkar, Ph.D., has uncovered astounding new insights into the development and progression of liver cancer, identifying key genetic drivers and shedding light on unknown associations with obesity and inflammation. Now, he and his colleagues have set their sights on immune cells found in the liver called macrophages, and their findings could lead to novel treatment approaches.
In the Cellular Immunotherapy and Transplantation Program at Virginia Commonwealth University Massey Cancer Center, scientists are pursuing a cross-collaborative effort that could potentially change the way cellular immunotherapies such as stem cell transplantation and CAR T-cell therapies are performed. This grassroots research is funded primarily through VCU Massey pilot grants, and it is culminating in a first-of-its-kind body of work that provides a detailed quantitative view of how the immune system responds to cellular therapies.
Research conducted by scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the journal Cancer Research, could lead to new and improved treatments for AML and other hematologic malignancies.
Palliative care consultations administered within three days of admission are linked to shorter hospitalizations and significant cost savings for chronically ill adults, according to a large meta-analysis study involving researchers at VCU Massey Cancer Center.